<DOC>
	<DOCNO>NCT01773434</DOCNO>
	<brief_summary>This multicenter , multiple dos , open-label Phase 1 study MORAb-004 subject solid tumor . Subjects may solid tumor without intracranial involvement metastasis fail standard chemotherapy . This study conduct 2 part : 1 ) Part 1 dose escalation portion study ass tolerability safety profile MORAb-004 . Dose escalate different cohort follow : 2 , 4 , 8 12 mg/kg weekly dose 4-week cycle intra-subject escalation . Individual participant may additional cycle dose disease progression unless participant meet discontinuation criterion . 2 ) Part 2 comprise cohort expansion characterize safety tolerability MORAb-004 ass preliminary efficacy pharmacokinetic/pharmacodynamic relationship MORAb-004 gastric cancer hepatocellular carcinoma ( HCC ) . Three dose level expand base safety profile obtain dose escalation portion study ( Part 1 ) : 4 mg/kg ( administered weekly basis ) , 8 mg/kg ( administered weekly basis ) 12 mg/kg ( administer every OTHER week ) .</brief_summary>
	<brief_title>A Phase 1 Study MORAb-004 Patients With Solid Tumor ( Study : MORAb-004-J081-103 )</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Provide write informed consent , 2 . Japanese male female subject age 20 old inform consent , 3 . Have malignant solid tumor , without intracranial involvement metastasis , diagnosed standard pathology criterion fail resistant standard chemotherapy , 4 . Performance status ( PS ) 0 1 Eastern Cooperative Oncology Group , 5 . With carryover effect adverse drug reaction prior treatment may affect safety evaluation MORAb004 , except Grade 1 2 neuropathy alopecia , 6 . Survival expectation 12 week longer start MORAb004 administration Exclusion criterion : 1 . Have clinically significant cardiovascular disease , 2 . Scheduled laparotomic surgery due trauma reason study , 3 . Have clinically significant hemorrhagic event history , event high risk hemorrhage , 4 . Receiving chronic systemic anticoagulation , 5 . Have evidence active invasive malignancy 6 . Females lactate pregnant Screening Baseline</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>